This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new indications and recent first-time generic launches.

This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new indications and recent first-time generic launches.

Annual conference gathers 2,500+ managed care leaders to discuss complex health care issues.

Read Drug Approvals Monthly Update: January 2024 Critical updates in an ever-changing environment. Drug Approval Update Specialty New drugs 12/22/2023 Wainua™ (eplontersen) The United States (U.S.)...

Read Drug Approvals Monthly Update: February 2024 This monthly approval update provides a review of newly approved specialty drugs, recent drug launches, generic updates, new indications and news...

publications Spring 2024 Prime Therapeutics Report March 15, 2024 The Prime Therapeutics Report is your source for innovative managed care strategies, trends and updates. Our cover story (Page 6)...

13th annual report the preeminent source for medical benefit drug trend

Managed Healthcare Executive

publications High-Cost Therapy Profile: March 2025 Pegzilarginase Intravenous (IV), Subcutaneous (SC) | Immedica Metabolic March 14, 2025 Proposed indications Arginase 1 deficiency (ARG1-D)...

Get the most value and best outcomes from C&GT Cell and gene therapies (C&GTs) represent breakthrough science, but often come at a high cost. Breadcrumb Home Our solutions Condition management Cell...

Breadcrumb Home Newsroom Custom Content Publications Drug Approvals Monthly Update: September 2024 PUBLICATIONS Drug Approvals Monthly Update: September 2024 This monthly update of United States...

Biobetters are just a nickname; they’re based on existing biologics but with a few key differences

Read Drug Approvals Monthly Update: June 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new...

PUBLICATIONS FDA Decisions Expected Drug pipeline for January 2025 December 17, 2024 Your monthly synopsis of new drugs expected to hit the market At Prime Therapeutics (Prime), we have positioned...

Breadcrumb Home Read, watch, listen Read Explore what's trending at Prime Example Link Example Link Card Title example Example Link Example Link Card Title example The Latest Tab 1 Press Releases...

Perspectives High-Cost Therapy Profile: April Detailed information about prademagene zamikeracel Topical surgical application Date High Cost Therapy Profile Gene therapy/Dermatology Prademagene...

Read Drug Approvals Monthly Update: April 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new...

Perspectives High-Cost Therapy Profile: May Detailed information about Fidanacogene elaparvovec-dzkt Intravenous (IV) High Cost Therapy Profile Gene therapy/Hematology Fidanacogene elaparvovec-dzkt...

Drug Approvals Quarterly Update: July 2024 This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process....

PUBLICATIONS FDA Decisions Expected: March 2025 Your monthly synopsis of new drugs expected to hit the market February 14, 2025 Drug pipeline for March 2025 At Prime Therapeutics (Prime), we have...

publications FDA Decisions Expected Drug pipeline for November 2024 October 14, 2024 Your monthly synopsis of new drugs expected to hit the market At Prime Therapeutics (Prime), we have...

Read Drug Approvals Monthly Update: May 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new...

Managed Healthcare Executive

USA Today

Reuters

Insider

CNBC

Formulary Watch

Star Tribune

Business Insider

Endpoint News

publications High Cost Therapy Profile: November 2024 Zenocutuzumab Intravenous (IV) November 20, 2024 Oncology Proposed indications Pancreatic ductal adenocarcinoma (PDAC) and non–small...

Reuters

Reuters

Washington Post: Doctors and patients struggle with starting and stopping medications with little guidance.

Reuters

Reuters

NBC News: Patients weren't asked why they quit taking the weight loss drugs

PUBLICATIONS FDA Decisions Expected: June 2025 Your monthly synopsis of new drugs expected to hit the market May 21, 2025 Drug pipeline for June 2025 At Prime Therapeutics (Prime), we have...

Jessica Johnson, clinical consultant at Prime Therapeutics, shares how the Special Investigations Unit (SIU) helps prevent fraud, waste and abuse (FWA) in health care

For the first time, Prime Therapeutics hosted the AMCP Nexus specialty keynote, addressing trends in cell and gene therapy and rare disease and immunology categories

research 8 research posters presented by Prime at the 2024 AMCP Annual Meeting Prime remains at the forefront of researching real-world drug utilization, managed care pharmacy programs, and costs...

AMCP Annual Meeting 2025 research posters Studies include Prime’s GLP-1 obesity research and a Medicare drug cost predictive model Click on the poster image to view the full-size version. Prime...

Drs. Tracey Garcia and Amy Pappas, board-certified neurologists, reviewed migraine risk factors and treatments in a recent webinar moderated by Dr. Marci Chodroff, vice president of medical affairs

Breadcrumb Home Newsroom Custom Content Publications FDA Decisions Expected: October 2024 PUBLICATIONS FDA Decisions Expected: October 2024 Your monthly synopsis of new drugs expected to hit the...

Read Drug Approvals Monthly Update: August 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new...

publications Weight management: A holistic journey May 1, 2024 Obesity is a global epidemic and major public health issue that has grown in prevalence over recent decades in adults, adolescents...

PUBLICATIONS FDA Decisions Expected: July 2025 Your monthly synopsis of new drugs expected to hit the market June 18, 2025 Drug pipeline for July 2025 At Prime Therapeutics (Prime), we have...

Marquee event showcased new Prime, our energy, ambition and transformative journey

Perspectives High-Cost Therapy Profile: March Detailed information about Sotatercept Subcutaneous (SC) High Cost Therapy Profile Cardiovascular Sotatercept Subcutaneous (SC) Merck/Bristol-Myers...

publications High-Cost Therapy Profile: June 2025 Zopapogene imadenovec Subcutaneous (SC) | Precigen, Inc. Infectious Disease June 18, 2025 Proposed indications Recurrent respiratory...

Drug Approvals Quarterly Update: April 2024 This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process....

publications High Cost Therapy Profile: January 2025 Tabelecleucel Intravenous (IV) Oncology January 8, 2025 Proposed indications Epstein-Barr virus-positive (EBV+) post-transplant...

Help lower costs with biosimilars We actively promote evidence-based use of biosimilars to help you make the most of your integrated drug strategy. Breadcrumb Home Our solutions Condition...

Special Investigations Unit helps promote safety to prevent fraud, waste and abuse schemes

publications Drug Approvals: July 2024 Monthly update on newly approved specialty and traditional drugs, new indications and first-time generic launches July 31, 2024 Specialty New drugs Jun. 20,...

Expert Clinical Network Insights Hemophilia December 17, 2024 Medication insights: marstacimab-hncq (Hympavzi) The U.S. Food and Drug Administration (FDA) approved marstacimab-hncq (Hympavzi) in...

publications Drug Approvals: February 2025 Monthly update on newly approved specialty and traditional drugs, new indications and first-time generic launches February 28, 2025 Specialty New drugs...

Stories, perspectives and news coverage of Prime Therapeutics/Magellan Rx from AMCP 2024

In this episode, our experts discuss Prime’s four primary tenets of practice for chronic weight management.